Immunophotonics, Inc. has completed its multicentre clinical trial (SAKK 66/17) conducted in collaboration with the Swiss Cancer Institute (formerly known as SAKK).
Along with completion of its INJECTABL-1 trial covering different indications, which was announced in July 2025, the company said this marks an advance in evaluating the immunologically mediated anticancer effects of intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumours.
The SAKK 66/17 trial was designed to assess the safety and tolerability of IP-001 in combination with thermal ablation in patients with various types of advanced solid tumours, with a second phase assessing efficacy for melanoma and soft-tissue sarcoma. With treatment completed for all patients in both phases, data analysis is now underway.
Markus Joerger, principal investigator for the study at the Cantonal Hospital St. Gallen Clinic for Medical Oncology and Hematology, said: “This collaboration between Immunophotonics and Swiss Cancer Institute highlights the importance of partnerships in advancing cancer treatments. With the completion of this trial, we made the next important step in the development of a new treatment option for patients with advanced solid tumors. The results could have a meaningful impact in the fight against cancer.”
The results of this trial provide further evidence regarding safety and efficacy of IP-001 in a broader patient population.
IP-001 is a proprietary glycan polymer that generates tumour antigen depots and acts as a potent, multimodal immune stimulant intended to induce immunological responses to eradicate cancer. IP-001 is designed to prolong the availability of the targeted tumour antigens, facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), increase the uptake of the tumour antigens into the APCs, and lead to a downstream adaptive immune response against the tumour cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumour cells throughout the body.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
